First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

AIMS: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS‐962212, a first‐in‐class factor XIa inhibitor, in Japanese and non‐Japanese healthy subjects. METHODS: This was a randomized, placebo‐controlled, double‐blind, sequential, ascending‐...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Perera, Vidya, Luettgen, Joseph M., Wang, Zhaoqing, Frost, Charles E., Yones, Cynthia, Russo, Cesare, Lee, John, Zhao, Yue, LaCreta, Frank P., Ma, Xuewen, Knabb, Robert M., Seiffert, Dietmar, DeSouza, Mary, Mugnier, Pierre, Cirincione, Brenda, Ueno, Takayo, Frost, Robert J. A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5903252/
https://ncbi.nlm.nih.gov/pubmed/29346838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13520
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados